ATE449772T1 - Pyrrolderivate mit antagonistischer wirkung am crth2-rezeptor - Google Patents
Pyrrolderivate mit antagonistischer wirkung am crth2-rezeptorInfo
- Publication number
- ATE449772T1 ATE449772T1 AT05815747T AT05815747T ATE449772T1 AT E449772 T1 ATE449772 T1 AT E449772T1 AT 05815747 T AT05815747 T AT 05815747T AT 05815747 T AT05815747 T AT 05815747T AT E449772 T1 ATE449772 T1 AT E449772T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonistic effects
- crth2 receptor
- pyrrol derivatives
- pyrrol
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0427381.9A GB0427381D0 (en) | 2004-12-14 | 2004-12-14 | Organic compounds |
PCT/EP2005/013297 WO2006063763A1 (en) | 2004-12-14 | 2005-12-12 | Pyrrole derivatives having crth2 receptor antagonist activity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE449772T1 true ATE449772T1 (de) | 2009-12-15 |
Family
ID=34090028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05815747T ATE449772T1 (de) | 2004-12-14 | 2005-12-12 | Pyrrolderivate mit antagonistischer wirkung am crth2-rezeptor |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100087432A1 (de) |
EP (1) | EP1828172B1 (de) |
JP (1) | JP2008523130A (de) |
KR (1) | KR20070087605A (de) |
CN (1) | CN101072773B (de) |
AR (1) | AR052266A1 (de) |
AT (1) | ATE449772T1 (de) |
AU (1) | AU2005315881C1 (de) |
BR (1) | BRPI0518607A2 (de) |
CA (1) | CA2587934A1 (de) |
DE (1) | DE602005017935D1 (de) |
ES (1) | ES2335519T3 (de) |
GB (1) | GB0427381D0 (de) |
GT (1) | GT200500360A (de) |
MX (1) | MX2007007098A (de) |
PE (1) | PE20060736A1 (de) |
PL (1) | PL1828172T3 (de) |
PT (1) | PT1828172E (de) |
RU (1) | RU2007126761A (de) |
TW (1) | TW200635921A (de) |
WO (1) | WO2006063763A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0611695D0 (en) * | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
TW200848019A (en) * | 2007-03-06 | 2008-12-16 | Wyeth Corp | Aryl sulfonamides useful for modulation of the progesterone receptor |
SI2229358T1 (sl) | 2007-12-14 | 2011-10-28 | Pulmagen Therapeutics Asthma Ltd | Indoli in njihova terapevtska uporaba |
MA33134B1 (fr) * | 2009-02-24 | 2012-03-01 | Merck Canada Inc | Derives d'indole en tant qu'antagonistes du recepteur crth2 |
UY33110A (es) | 2009-12-23 | 2011-07-29 | Ironwood Pharmaceuticals Inc | Moduladores de CRTH2 |
BR112012024114B1 (pt) | 2010-03-22 | 2021-02-09 | Idorsia Pharmaceuticals Ltd | Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica |
WO2011117184A1 (de) | 2010-03-24 | 2011-09-29 | Bayer Cropscience Ag | Fludioxonil-derivate |
EP2457900A1 (de) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten |
US20140187795A1 (en) * | 2010-12-08 | 2014-07-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators and preparation thereof |
BR112013026283A8 (pt) | 2011-04-14 | 2018-01-30 | Actelion Pharmaceuticals Ltd | derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina |
EP2790696A1 (de) | 2011-12-16 | 2014-10-22 | Atopix Therapeutics Limited | Kombination von crth2-antagonisten und einem protonenpumpenhemmer zur behandlung von eosinophiler ösophagitis |
KR20140107550A (ko) | 2011-12-21 | 2014-09-04 | 액테리온 파마슈티칼 리미티드 | 헤테로시클릴 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 그의 용도 |
WO2013155422A1 (en) * | 2012-04-12 | 2013-10-17 | Ironwood Pharmaceuticals, Inc. | Methods of treating alopecia and acne |
WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
ES2461415B1 (es) * | 2012-10-16 | 2015-03-16 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados funcionalizados e inmunorreactivos para el fungicida fludioxonil |
CN103588686B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 一种用卤素卤化制备2-甲氧基-4-氨基-5-乙砜基苯甲酸甲酯的方法 |
CN103553990B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 用卤素卤化合成2-甲氧基-4-氨基-5-乙砜基苯甲酸甲酯的方法 |
CN103553991B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 一种制备2-甲氧基-4-氨基-5-乙砜基苯甲酸甲酯的方法 |
SI3119779T1 (sl) | 2014-03-17 | 2018-10-30 | Idorsia Pharmaceuticals Ltd | Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2 |
AU2015233046A1 (en) | 2014-03-18 | 2016-11-03 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
WO2017046125A1 (en) | 2015-09-15 | 2017-03-23 | Actelion Pharmaceuticals Ltd | Crystalline forms |
CN108164502B (zh) * | 2018-03-06 | 2021-04-13 | 苏州华一新能源科技有限公司 | 1,3-丙烷磺酸内酯的制备方法 |
CN112602714B (zh) * | 2020-12-23 | 2021-11-16 | 华南农业大学 | 一类咯菌腈羧酸衍生物在用于植物维管组织靶向药剂中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0182737A3 (de) * | 1984-10-16 | 1986-10-08 | Ciba-Geigy Ag | 3-Phenylpyrrolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
EP0386681A1 (de) * | 1989-03-08 | 1990-09-12 | Ciba-Geigy Ag | 3-Aryl-4-cyano-pyrrol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende mikrobiozide Mittel |
JP4316232B2 (ja) * | 2001-12-28 | 2009-08-19 | 武田薬品工業株式会社 | アンドロゲン受容体拮抗剤 |
EP1466902A4 (de) * | 2001-12-28 | 2005-11-09 | Takeda Pharmaceutical | Antagonisten des androgenrezeptors |
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
WO2005116001A1 (en) * | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Substituted thiazoleacetic as crth2 ligands |
-
2004
- 2004-12-14 GB GBGB0427381.9A patent/GB0427381D0/en not_active Ceased
-
2005
- 2005-12-07 GT GT200500360A patent/GT200500360A/es unknown
- 2005-12-12 US US11/720,786 patent/US20100087432A1/en not_active Abandoned
- 2005-12-12 PL PL05815747T patent/PL1828172T3/pl unknown
- 2005-12-12 AU AU2005315881A patent/AU2005315881C1/en not_active Ceased
- 2005-12-12 KR KR1020077013302A patent/KR20070087605A/ko active IP Right Grant
- 2005-12-12 EP EP05815747A patent/EP1828172B1/de not_active Not-in-force
- 2005-12-12 MX MX2007007098A patent/MX2007007098A/es active IP Right Grant
- 2005-12-12 RU RU2007126761/04A patent/RU2007126761A/ru not_active Application Discontinuation
- 2005-12-12 WO PCT/EP2005/013297 patent/WO2006063763A1/en active Application Filing
- 2005-12-12 JP JP2007545917A patent/JP2008523130A/ja active Pending
- 2005-12-12 DE DE602005017935T patent/DE602005017935D1/de active Active
- 2005-12-12 BR BRPI0518607-2A patent/BRPI0518607A2/pt not_active IP Right Cessation
- 2005-12-12 ES ES05815747T patent/ES2335519T3/es active Active
- 2005-12-12 AR ARP050105197A patent/AR052266A1/es not_active Application Discontinuation
- 2005-12-12 PT PT05815747T patent/PT1828172E/pt unknown
- 2005-12-12 PE PE2005001434A patent/PE20060736A1/es not_active Application Discontinuation
- 2005-12-12 CN CN2005800416868A patent/CN101072773B/zh not_active Expired - Fee Related
- 2005-12-12 AT AT05815747T patent/ATE449772T1/de not_active IP Right Cessation
- 2005-12-12 CA CA002587934A patent/CA2587934A1/en not_active Abandoned
- 2005-12-13 TW TW094143970A patent/TW200635921A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AR052266A1 (es) | 2007-03-07 |
PE20060736A1 (es) | 2006-09-08 |
AU2005315881A1 (en) | 2006-06-22 |
TW200635921A (en) | 2006-10-16 |
CN101072773A (zh) | 2007-11-14 |
PT1828172E (pt) | 2010-02-17 |
DE602005017935D1 (de) | 2010-01-07 |
GB0427381D0 (en) | 2005-01-19 |
GT200500360A (es) | 2006-08-07 |
EP1828172B1 (de) | 2009-11-25 |
AU2005315881B2 (en) | 2009-09-24 |
MX2007007098A (es) | 2007-06-22 |
RU2007126761A (ru) | 2009-01-27 |
JP2008523130A (ja) | 2008-07-03 |
AU2005315881C1 (en) | 2010-03-11 |
BRPI0518607A2 (pt) | 2008-11-25 |
WO2006063763A1 (en) | 2006-06-22 |
ES2335519T3 (es) | 2010-03-29 |
EP1828172A1 (de) | 2007-09-05 |
PL1828172T3 (pl) | 2010-05-31 |
CA2587934A1 (en) | 2006-06-22 |
KR20070087605A (ko) | 2007-08-28 |
US20100087432A1 (en) | 2010-04-08 |
CN101072773B (zh) | 2011-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE449772T1 (de) | Pyrrolderivate mit antagonistischer wirkung am crth2-rezeptor | |
DE60332125D1 (de) | Indole mit antidiabetischer wirkung | |
DK1824856T3 (da) | 2,4 (4,6)-pyrimidinderivater | |
ATE512960T1 (de) | Pyrimidinderivate | |
DK1833791T3 (da) | 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister | |
ATE390423T1 (de) | Benzoazolylpiperazinderivate mit vr1- antagonistischer wirkung | |
IS8578A (is) | 3- karbamoýl - 2- pýridón afleiður | |
MA28824B1 (fr) | Derives de pyrimidine | |
ATE383361T1 (de) | Pyrrazolopyrimidinderivate | |
ATE394399T1 (de) | Tetrahydropyridoindolderivate | |
DE602005011236D1 (de) | Modulationsbereichstrigger | |
DE602005001370D1 (de) | Dispersionskompensator mit Wellenlängennachführung | |
ATE487718T1 (de) | Substituierte bizyklische pyrimidonderivate | |
DE602004021572D1 (de) | SUBSTITUIERTE 8-PERFLUORO-6,7,8,9-TETRAHYDROPYRIMIDOi1,2-A PYRIMIDIN-4-ON-DERIVATE | |
ATE454377T1 (de) | 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor | |
ATE369358T1 (de) | Substituierte benzoylderivate als herbizide | |
DE602005017683D1 (de) | Winkelverstellvorrichtung | |
DE602005026846D1 (de) | Scharnieranordnung | |
ATE365731T1 (de) | 4-amino-5-cyanopyrimidinderivate | |
ATE361282T1 (de) | Indazol-aminoacetonitrilderivate mit pestizider wirkung | |
ATE446750T1 (de) | 3-cyano-chinolin-derivate mit antiproliferativer wirkung | |
DE60328272D1 (de) | Diazabicycloalkan-derivate mit nk1-antagonistischer wirkung | |
ATE445604T1 (de) | Neue 2,6-diaminopyridin-3-on-derivate | |
DE602004027792D1 (de) | Indazolamide mit analgetischer wirkung | |
ATE444288T1 (de) | Pyrrolidinderivate mit wirkung am glyt1- transporter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1828172 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |